AFG
FATE icon

Albion Financial Group’s Fate Therapeutics FATE Stock Holding History

Albion Financial Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270 Hold
225
– – ﹤0.01% 705
2025
Q4 		$222 Hold
225
– – ﹤0.01% 629
2025
Q3 		$284 Hold
225
– – ﹤0.01% 626
2025
Q2 		$252 Hold
225
– – ﹤0.01% 561
2025
Q1 		$178 Hold
225
– – ﹤0.01% 582
2024
Q4 		$372 Hold
225
– – ﹤0.01% 646
2024
Q3 		$788 Hold
225
– – ﹤0.01% 465
2024
Q2 		$738 Hold
225
– – ﹤0.01% 468
2024
Q1 		$1.65K Hold
225
– – ﹤0.01% 426
2023
Q4 		$842 Hold
225
– – ﹤0.01% 435
2023
Q3 		$477 Hold
225
– – ﹤0.01% 444
2023
Q2 		$1.07K Hold
225
– – ﹤0.01% 413
2023
Q1 		$1.28K Hold
225
– – ﹤0.01% 390
2022
Q4 		$2.27K Hold
225
– – ﹤0.01% 377
2022
Q3 		$5K Hold
225
– – ﹤0.01% 344
2022
Q2 		$6K Hold
225
– – ﹤0.01% 342
2022
Q1 		$9K Hold
225
– – ﹤0.01% 370
2021
Q4 		$13K Buy
225
+35
+18% +$1.98K ﹤0.01% 390
2021
Q3 		$11K Hold
190
– – ﹤0.01% 362
2021
Q2 		$16K Buy
+190
New +$15.3K ﹤0.01% 348
2020
Q4 		$13K Buy
+140
New +$8.69K ﹤0.01% 334

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Albion Financial Group's FATE Position: Q1 2026 in Review

Albion Financial Group held its Fate Therapeutics (FATE) position steady in Q1 2026 at 225 shares worth $270. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Albion Financial Group first reported a position in FATE in Q4 2020 and has held it in 21 quarters since. The position peaked at $16K in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Albion Financial Group held 225 shares of Fate Therapeutics worth $270 as of Q1 2026.
  • Albion Financial Group left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Albion Financial Group's portfolio in Q1 2026, its #705 holding.
  • Albion Financial Group first reported a position in Fate Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Albion Financial Group's Fate Therapeutics position peaked at $16K in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Albion Financial Group's 13F filing for Q1 2026, filed 27 Apr 2026.